This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | MicrobiomeTrials
← Back to trials NCT07725406
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-11Est. Completion: 2028-08-01
Enrollment target: 32 participantsLocations Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States Other microbiome trials you might be interested in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin …
Duarte, United States Est. completion Jun 30, 2027
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Multiple Myeloma Progression Multiple Myeloma Refractory
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatmen…
Copenhagen, Denmark Est. completion Jun 30, 2027